Cassava Sciences (SAVA) 10-Q 8 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 10, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	PTIE
Entity Registrant Name	PAIN THERAPEUTICS INC
Entity Central Index Key	1069530
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		45,756,117

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$37,249	$40,590	[1]
Marketable securities	1,999
Other current assets	119	239	[1]
Total current assets	39,367	40,829	[1]
Property and equipment, net	256	65	[1]
Other assets	12	12	[1]
Total assets	39,635	40,906	[1]
Current liabilities:
Accounts payable	255	173	[1]
Accrued development expense	207	25	[1]
Accrued compensation and benefits	738	652	[1]
Total current liabilities	1,200	850	[1]
Noncurrent liabilities			[1]
Total liabilities	1,200	850	[1]
Commitments and contingencies			[1]
Stockholders' equity:
Preferred stock			[1]
Common stock	46	46	[1]
Additional paid-in capital	157,464	156,502	[1]
Accumulated other comprehensive income	1	1	[1]
Accumulated deficit	-119,076	-116,493	[1]
Total stockholders' equity	38,435	40,056	[1]
Total liabilities and stockholders' equity	$39,635	$40,906	[1]
[1]	Derived from the Company’s audited financial statements as of December 31, 2014, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Condensed_Statements_Of_Operat

Condensed Statements Of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
Research and development	$1,138	$2,147
General and administrative	1,457	1,317
Total operating expenses	2,595	3,464
Operating loss	-2,595	-3,464
Interest income	12	14
Net loss	($2,583)	($3,450)
Net loss per share, basic and diluted	($0.06)	($0.08)
Weighted-average shares used in computing net loss per share, basic and diluted	45,356	45,127

Condensed_Statements_Of_Compre

Condensed Statements Of Comprehensive Loss (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Condensed Statements Of Comprehensive Loss [Abstract]
Net loss	($2,583)	($3,450)
Other comprehensive income (losses):
Net unrealized losses on marketable securities
Comprehensive loss	($2,583)	($3,450)

Condensed_Statements_Of_Cash_F

Condensed Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014
Cash flows used in operating activities:
Net loss	($2,583)		($3,450)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock based compensation	962		783
Depreciation and amortization	4		3
Changes in operating assets and liabilities:
Other current assets	120		124
Accounts payable	82		-17
Accrued development expense	182		-340
Accrued compensation and benefits	86		167
Other current liabilities			7
Net cash used in operating activities	-1,147		-2,723
Cash flows used in investing activities:
Purchases of property and equipment	-195		-79
Purchases of marketable securities	-1,999		-1,250
Maturities of marketable securities			1,250
Net cash used in investing activities	-2,194		-79
Cash flows provided by financing activities:
Proceeds from issuance of common stock, net			66
Net cash provided by financing activities			66
Net decrease in cash and cash equivalents	-3,341		-2,736
Cash and cash equivalents at beginning of the period	40,590	[1]	48,588
Cash and cash equivalents at end of the period	$37,249		$45,852
[1]	Derived from the Company’s audited financial statements as of December 31, 2014, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

General

General	3 Months Ended
	Mar. 31, 2015
General [Abstract]
General	Note 1.  General
	We are a biopharmaceutical company that develops novel drugs. We own world-wide commercial rights to our lead drug candidate, REMOXY Extended-Release Capsules CII, a unique, twice-a-day formulation of oral oxycodone.  REMOXY’s intended indication is for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time and for which alternative treatments are inadequate.  We specifically developed REMOXY to discourage certain common methods of drug tampering and misuse. The REMOXY NDA is supported by multiple clinical trials, including a successful Phase III efficacy program that was conducted under a Special Protocol Assessment.
	In the course of our development activities, we have sustained cumulative operating losses. There are no assurances that additional financing will be available on favorable terms, or at all.
	We have prepared the accompanying unaudited condensed financial statements of Pain Therapeutics, Inc. in accordance with generally accepted accounting principles for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for any other interim period or for the year 2015.  For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2014.
	We have evaluated subsequent events through the date of filing this Form 10-Q.

Significant_Accounting_Policie

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 2.  Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.
	Cash, Cash Equivalents and Concentration of Credit Risk
	We consider all highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist of cash maintained at one financial institution and in money market funds. We believe the financial risks associated with these instruments are minimal. We have not experienced material losses from our investments in these securities.
	Marketable Securities and Fair Value Measurements
	We invest in interest bearing marketable securities, generally consisting of corporate and government securities. We may elect to sell these investments before they mature. Therefore, we hold these investments as “available for sale” and include these investments in our balance sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year. We report our marketable securities at fair value, which may include unrealized gains and losses. Our unrealized gains and losses on investments are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. We recognize all realized gains and losses on our marketable securities on a specific identification basis in interest income in our Statements of Operations. We report changes in net unrealized gains or losses on marketable securities in our Statements of Comprehensive Income. Our marketable securities are maintained at one financial institution and are governed by our investment policy as approved by our Board of Directors.
	To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. We would recognize an impairment charge when the decline in the estimated fair value of a marketable security below the amortized cost is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery.
	We measure our cash equivalents and marketable securities at fair value on a recurring basis.  We use significant observable inputs where there are identical or comparable assets in the market to use in establishing our fair value measurements, including but not limited to benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We consider these inputs to be Level 2 inputs. Generally, the types of instruments we invest in are not traded on a market such as the NASDAQ Global Market, which we would consider to be Level 1 inputs. We do not have any investments that would require inputs considered to be Level 3. We use the bid price to establish fair value where a bid price is available.
	Stock-based Compensation
	We recognize expense for the fair value of all share-based payments, including grants of employee stock options and other share based awards, in our Statements of Operations. For stock options, we use the Black-Scholes option valuation model and the single-option award approach and straight-line attribution method. Using this approach, the compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally four years. We estimate forfeitures and adjust this estimate periodically based on the extent to which future actual forfeitures differ, or are expected to differ, from such estimates.
	We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. The value of these awards is the product of the number of shares of our common stock to be issued under the award multiplied by the fair market value of a share of our common stock on the date of grant. These awards include future performance criteria. We estimate an implicit service period for achieving these performance criteria. Performance Awards vest and common stock is issued on achieving performance criteria. We recognize stock-based compensation expense for Performance Awards when we conclude that achieving performance criteria is probable. We periodically review and update as appropriate our estimates of the implicit service periods and the likelihood of achieving the performance criteria.
	Net Loss per Share
	We compute basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. We compute diluted net loss per share on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and Performance Awards.
	The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands except per share data):
		Three months ended
		March 31,
		2015		2014
	Numerator:
	Net loss	$	-2,583	$	-3,450
	Denominator:
	Weighted-average shares used to compute basic net loss per share		45,356		45,127
	Net loss per share, basic and diluted	$	-0.06	$	-0.08
	We excluded weighted options outstanding to purchase common stock of 17.8 million for the first quarter of 2015 and 4.5 million for the first quarter of 2014 from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.
	Income Taxes
	We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance. We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our statement of operations in that period. We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

Cash_Cash_Equivalents_And_Mark

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value	3 Months Ended
	Mar. 31, 2015
Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value [Abstract]
Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value	Note 3.  Cash, Cash Equivalents and Marketable Securities and Assets Measured at Fair Value
	Our cash, cash equivalents and marketable securities are as follows (in thousands):
			Cash, Cash Equivalents and Marketable Securities
			Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
		31-Mar-15
		Cash	$	227	$	—	$	—	$	227	$	—	$	227
		Cash equivalents		34,022		—		—		34,022		—		34,022
		Commercial paper		4,998		1		—		4,999		—		4,999
			$	39,247	$	1	$	—	$	39,248	$	—	$	39,248
		Reported as:
		Cash and cash equivalents	$	37,249	$	—	$	—	$	37,249	$	—	$	37,249
		Marketable securities		1,998		1		—		1,999		—		1,999
			$	39,247	$	1	$	—	$	39,248	$	—	$	39,248
		Maturities:
		Matures in one year or less	$	39,247	$	1	$	—	$	39,248	$	—	$	39,248
		Matures one to three years		—		—		—		—		—		—
			$	39,247	$	1	$	—	$	39,248	$	—	$	39,248
		31-Dec-14
		Cash	$	295	$	—	$	—	$	295	$	—	$	295
		Cash equivalents		34,805		—		—		34,805		—		34,805
		Commercial paper		4,848		1		—		4,849		—		4,849
		Corporate securities		631		—		—		631		10		641
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Reported as:
		Cash and cash equivalents	$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Maturities:
		Matures in one year or less	$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Matures one to three years		—		—		—		—		—		—
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
	We did not realize any gains or losses on our investments in marketable securities during the first three months of 2015 or 2014. To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.
	Our assets measured at fair value on a recurring basis are as follows (in thousands):
			Level 1		Level 2		Level 3		Total
		31-Mar-15
		Cash and cash equivalents	$	34,249	$	—	$	—	$	34,249
		Commercial paper		—		4,999		—		4,999
		Corporate securities		—		—		—		—
			$	34,249	$	4,999	$	—	$	39,248
		31-Dec-14
		Cash and cash equivalents	$	35,100	$	—	$	—	$	35,100
		Commercial paper		—		4,849		—		4,849
		Corporate securities		—		641		—		641
			$	35,100	$	5,490	$	—	$	40,590

Equity_And_StockBased_Compensa

Equity And Stock-Based Compensation Expense	3 Months Ended
	Mar. 31, 2015
Equity And Stock-Based Compensation Expense [Abstract]
Equity And Stock-Based Compensation Expense	Note 4.  Equity and Stock-Based Compensation Expense
	Our stock option and Performance Award activity during 2015 was as follows:
		Number of Options		Number of Performance Awards
	Outstanding as of December 31, 2014	17,913,182		1,889,465
	Granted	—		—
	Exercised	—		—
	Cancelled	-166,995		-50,000
	Outstanding as of March 31, 2015	17,746,187		1,839,465
	Our non-cash stock-based compensation expenses were as follows (in thousands):
		Three months ended
		March 31,
		2015			2014
	Research and development	$	334		$	348
	General and administrative		628			435
		$	962		$	783

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Taxes [Abstract]
Income Taxes	Note 5.  Income Taxes
	We did not provide for income taxes in 2015 because we have projected a net loss for the full year 2015.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2015
Commitments [Abstract]
Commitments	Note 6.  Commitments
	We conduct our product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations that are cancelable. Our obligations under these contracts are largely based on services performed.
	We have a non-cancelable operating lease for approximately 6,000 square feet of office space in Austin, TX that expires in December 2017.  Minimum lease payments are as follows (in thousands):
		2015		2016		2017		Total
	Minimum lease payments	$	143	$	146	$	147	$	436

Legal_Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2015
Legal Proceedings [Abstract]
Legal Proceedings
	Note 7.  Legal proceedings
	KB Partners I, L.P., Individually and On Behalf of All Others Similarly Situated v. Pain Therapeutics, Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy.
	On December 2, 2011, a purported class action was filed against us and our executive officers in the U.S. District Court for the Western District of Texas. This complaint alleges, among other things, violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act arising out of allegedly untrue or misleading statements of material facts made by us regarding REMOXY’s development and regulatory status during the purported class period, February 3, 2011 through June 23, 2011. The complaint states that monetary damages are being sought, but no amounts are specified. On June 3, 2013, the Court certified a class consisting of all purchasers of our common stock and a class period of December 27, 2010 through June 26, 2011.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	3 Months Ended
	Mar. 31, 2015
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements	Note 8.  Recently Issued Accounting Pronouncements
	We reviewed recently issued accounting pronouncements and have adopted or plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.

Significant_Accounting_Policie1

Significant Accounting Policies (Policy)	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Use Of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.
Cash, Cash Equivalents And Concentration Of Credit Risk	Cash, Cash Equivalents and Concentration of Credit Risk
	We consider all highly liquid financial instruments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist of cash maintained at one financial institution and in money market funds. We believe the financial risks associated with these instruments are minimal. We have not experienced material losses from our investments in these securities.
Marketable Securities And Fair Value Measurements	Marketable Securities and Fair Value Measurements
	We invest in interest bearing marketable securities, generally consisting of corporate and government securities. We may elect to sell these investments before they mature. Therefore, we hold these investments as “available for sale” and include these investments in our balance sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year. We report our marketable securities at fair value, which may include unrealized gains and losses. Our unrealized gains and losses on investments are recorded as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. We recognize all realized gains and losses on our marketable securities on a specific identification basis in interest income in our Statements of Operations. We report changes in net unrealized gains or losses on marketable securities in our Statements of Comprehensive Income. Our marketable securities are maintained at one financial institution and are governed by our investment policy as approved by our Board of Directors.
	To date we have not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value. We would recognize an impairment charge when the decline in the estimated fair value of a marketable security below the amortized cost is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery.
	We measure our cash equivalents and marketable securities at fair value on a recurring basis.  We use significant observable inputs where there are identical or comparable assets in the market to use in establishing our fair value measurements, including but not limited to benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We consider these inputs to be Level 2 inputs. Generally, the types of instruments we invest in are not traded on a market such as the NASDAQ Global Market, which we would consider to be Level 1 inputs. We do not have any investments that would require inputs considered to be Level 3. We use the bid price to establish fair value where a bid price is available.
Stock-Based Compensation	Stock-based Compensation
	We recognize expense for the fair value of all share-based payments, including grants of employee stock options and other share based awards, in our Statements of Operations. For stock options, we use the Black-Scholes option valuation model and the single-option award approach and straight-line attribution method. Using this approach, the compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally four years. We estimate forfeitures and adjust this estimate periodically based on the extent to which future actual forfeitures differ, or are expected to differ, from such estimates.
	We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. The value of these awards is the product of the number of shares of our common stock to be issued under the award multiplied by the fair market value of a share of our common stock on the date of grant. These awards include future performance criteria. We estimate an implicit service period for achieving these performance criteria. Performance Awards vest and common stock is issued on achieving performance criteria. We recognize stock-based compensation expense for Performance Awards when we conclude that achieving performance criteria is probable. We periodically review and update as appropriate our estimates of the implicit service periods and the likelihood of achieving the performance criteria.
Net Loss Per Share	Net Loss per Share
	We compute basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. We compute diluted net loss per share on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding stock options and Performance Awards.
	The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands except per share data):
		Three months ended
		March 31,
		2015		2014
	Numerator:
	Net loss	$	-2,583	$	-3,450
	Denominator:
	Weighted-average shares used to compute basic net loss per share		45,356		45,127
	Net loss per share, basic and diluted	$	-0.06	$	-0.08
	We excluded weighted options outstanding to purchase common stock of 17.8 million for the first quarter of 2015 and 4.5 million for the first quarter of 2014 from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.
Income Taxes	Income Taxes
	We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year. We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance. We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our statement of operations in that period. We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share
		Three months ended
		March 31,
		2015		2014
	Numerator:
	Net loss	$	-2,583	$	-3,450
	Denominator:
	Weighted-average shares used to compute basic net loss per share		45,356		45,127
	Net loss per share, basic and diluted	$	-0.06	$	-0.08

Cash_Cash_Equivalents_And_Mark1

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value (Tables)	3 Months Ended
	Mar. 31, 2015
Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value [Abstract]
Cash, Cash Equivalents And Marketable Securities
			Cash, Cash Equivalents and Marketable Securities
			Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Accrued Interest		Total Value
		31-Mar-15
		Cash	$	227	$	—	$	—	$	227	$	—	$	227
		Cash equivalents		34,022		—		—		34,022		—		34,022
		Commercial paper		4,998		1		—		4,999		—		4,999
			$	39,247	$	1	$	—	$	39,248	$	—	$	39,248
		Reported as:
		Cash and cash equivalents	$	37,249	$	—	$	—	$	37,249	$	—	$	37,249
		Marketable securities		1,998		1		—		1,999		—		1,999
			$	39,247	$	1	$	—	$	39,248	$	—	$	39,248
		Maturities:
		Matures in one year or less	$	39,247	$	1	$	—	$	39,248	$	—	$	39,248
		Matures one to three years		—		—		—		—		—		—
			$	39,247	$	1	$	—	$	39,248	$	—	$	39,248
		31-Dec-14
		Cash	$	295	$	—	$	—	$	295	$	—	$	295
		Cash equivalents		34,805		—		—		34,805		—		34,805
		Commercial paper		4,848		1		—		4,849		—		4,849
		Corporate securities		631		—		—		631		10		641
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Reported as:
		Cash and cash equivalents	$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Maturities:
		Matures in one year or less	$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
		Matures one to three years		—		—		—		—		—		—
			$	40,579	$	1	$	—	$	40,580	$	10	$	40,590
Assets Measured At Fair Value On Recurring Basis
			Level 1		Level 2		Level 3		Total
		31-Mar-15
		Cash and cash equivalents	$	34,249	$	—	$	—	$	34,249
		Commercial paper		—		4,999		—		4,999
		Corporate securities		—		—		—		—
			$	34,249	$	4,999	$	—	$	39,248
		31-Dec-14
		Cash and cash equivalents	$	35,100	$	—	$	—	$	35,100
		Commercial paper		—		4,849		—		4,849
		Corporate securities		—		641		—		641
			$	35,100	$	5,490	$	—	$	40,590

Equity_And_StockBased_Compensa1

Equity And Stock-Based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2015
Equity And Stock-Based Compensation Expense [Abstract]
Stock Option And Performance Award Activity
		Number of Options		Number of Performance Awards
	Outstanding as of December 31, 2014	17,913,182		1,889,465
	Granted	—		—
	Exercised	—		—
	Cancelled	-166,995		-50,000
	Outstanding as of March 31, 2015	17,746,187		1,839,465
Summary Of Non-Cash Stock-Based Compensation
		Three months ended
		March 31,
		2015			2014
	Research and development	$	334		$	348
	General and administrative		628			435
		$	962		$	783

Commitments_Tables

Commitments (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments [Abstract]
Future Minimum Lease Payments
		2015		2016		2017		Total
	Minimum lease payments	$	143	$	146	$	147	$	436

Significant_Accounting_Policie3

Significant Accounting Policies (Narrative) (Details)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
	item
Significant Accounting Policies [Abstract]
Contractual maturity of a particular investment	1 year
Number of financial institutions	1
Vesting period of stock options	4 years
Anti-dilutive shares excluded from computation of diluted net loss per share	17.8	4.5

Significant_Accounting_Policie4

Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net loss	($2,583)	($3,450)
Denominator:
Weighted-average shares used to compute basic net loss per share	45,356	45,127
Net loss per share, basic and diluted	($0.06)	($0.08)

Cash_Cash_Equivalents_And_Mark2

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value (Cash, Cash Equivalents And Marketable Securities) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014		Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	$37,249	$40,590	[1]	$45,852	$48,588
Cash and cash equivalents, Short Term Investment, Amortized Cost	39,247	40,579
Cash and cash equivalents, Short Term Investment Unrealized Gains	1	1
Cash and cash equivalents, Short Term Investment Unrealized Losses
Accrued Interest		10
Estimated Fair Value, Marketable securities	1,999
Cash and cash equivalents, Short Term Investment, Fair Value	39,248	40,590
Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis	1,998
Available-for-sale securities, Gross Unrealized Gains	1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities	1,999
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash	227	295
Available-for-sale securities, Gross Unrealized Gains
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	227	295
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents	34,022	34,805
Available-for-sale securities, Gross Unrealized Gains
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	34,022	34,805
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis	4,998	4,848
Available-for-sale securities, Gross Unrealized Gains	1	1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities	4,999	4,849
Corporate Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis		631
Available-for-sale securities, Gross Unrealized Gains
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest		10
Estimated Fair Value, Marketable securities		641
Cash And Cash Equivalents, Reported Value [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	37,249	40,579
Available-for-sale securities, Gross Unrealized Gains		1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest		10
Cash and cash equivalents, Fair Value	37,249	40,590
Matures In One Year Or Less [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Amortized Cost	39,247	40,579
Available-for-sale securities, Gross Unrealized Gains	1	1
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest		10
Cash and cash equivalents, Short Term Investment, Fair Value	39,248	40,590
Matures One To Three Years [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Amortized Cost
Available-for-sale securities, Gross Unrealized Gains
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Short Term Investment, Fair Value
Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	39,248	40,580
Estimated Fair Value, Fair Value Disclosure [Member] | Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities	1,999
Estimated Fair Value, Fair Value Disclosure [Member] | Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	227	295
Estimated Fair Value, Fair Value Disclosure [Member] | Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	34,022	34,805
Estimated Fair Value, Fair Value Disclosure [Member] | Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities	4,999	4,849
Estimated Fair Value, Fair Value Disclosure [Member] | Corporate Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities		631
Estimated Fair Value, Fair Value Disclosure [Member] | Cash And Cash Equivalents, Reported Value [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	37,249	40,580
Estimated Fair Value, Fair Value Disclosure [Member] | Matures In One Year Or Less [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	39,248	40,580
Estimated Fair Value, Fair Value Disclosure [Member] | Matures One To Three Years [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value
[1]	Derived from the Company’s audited financial statements as of December 31, 2014, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Cash_Cash_Equivalents_And_Mark3

Cash, Cash Equivalents And Marketable Securities And Assets Measured At Fair Value (Assets Measured At Fair Value On Recurring Basis) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$39,248	$40,590
Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	34,249	35,100
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,999	4,849
Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		641
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	34,249	35,100
Level 1 [Member] | Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	34,249	35,100
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,999	5,490
Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	4,999	4,849
Level 2 [Member] | Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		641
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Corporate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value

Equity_And_StockBased_Compensa2

Equity And Stock-Based Compensation Expense (Stock Option And Performance Award Activity) (Details)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Number of Options, Outstanding	17,913,182
Number of Options, Cancelled	-166,995
Ending Balance, Number of Options, Outstanding	17,746,187
Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Number of Options, Outstanding	1,889,465
Number of Options, Cancelled	-50,000
Ending Balance, Number of Options, Outstanding	1,839,465

Equity_And_StockBased_Compensa3

Equity And Stock-Based Compensation Expense (Summary Of Non-Cash Stock-Based Compensation) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Stock-Based Compensation [Line Items]
Share Based Compensation	$962	$783
Research And Development [Member]
Stock-Based Compensation [Line Items]
Share Based Compensation	334	348
General And Administrative [Member]
Stock-Based Compensation [Line Items]
Share Based Compensation	$628	$435

Commitments_Narrative_Details

Commitments (Narrative) (Details) (Austin, TX [Member])	3 Months Ended
	Mar. 31, 2015
	sqft
Austin, TX [Member]
Operating Leased Assets [Line Items]
Office space	6,000
Operating lease expiration year	2017-12

Commitments_Future_Minimum_Lea

Commitments (Future Minimum Lease Payments) (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Contractual Obligation Fiscal Year Maturity Schedule [Abstract]
Future minimum lease payments, 2015	$143
Future minimum lease payments, 2016	146
Future minimum lease payments, 2017	147
Total	$436